Cases & Deals

  • Home
  • Practices
  • Idenix asserts patent infringement against Gilead in Australia related to Sovaldi® and Harvoni®

Share

Idenix asserts patent infringement against Gilead in Australia related to Sovaldi® and Harvoni®

April 2018

Client(s) Idenix Pharmaceuticals LLC

Jones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in the Federal Court of Australia over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C. The subject matter is nucleoside analogs and prodrugs for treating Flaviviridae infections, including HCV.

Gilead Sciences Pty Ltd v. Idenix Pharmaceuticals Inc & Ors, No NSD 48/2013 (Federal Court of Australia, January 17, 2013)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.